Table 1.
Ongoing clinical trials using angiotensin receptor AT1R blockers (ARBs) to inhibit the ACE/Ang-II/ATR1 axis of the renin–angiotensin system (RAS).
| Study title | Phase | Interventions | Sponsor | ClinicalTrials.gov identifier |
|---|---|---|---|---|
| Inhibition of the harmful arm of the RAS with ARBs | ||||
| Study of Open Label Losartan in COVID-19 | I | Losartan | University of Kansas Medical Center, USA | NCT04335123 |
| Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia | II | Chloroquine phosphate plus losartan vs. chloroquine phosphate | Hospital Universitario José E. Gonzalez Monterrey, Nuevo Leon, Mexico | NCT04428268 |
| Early Treatment with Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN) | II | Ivermectin plus losartan vs. placebo | Instituto do Cancer do Estado de Sao Paulo Sao Paulo, Brazil | NCT04447235 |
| Telmisartan for Treatment of COVID-19 Patients | II | Standard care plus telmisartan vs. standard care | Laboratorio Elea Phoenix S.A., Argentina | NCT04355936 |
| Losartan for Patients With COVID-19 Requiring Hospitalization | II | Losartan vs. placebo | University of Minnesota, USA | NCT04312009 |
| Losartan for Patients With COVID-19 Not Requiring Hospitalization | II | Losartan vs. placebo | University of Minnesota, USA | NCT04311177 |
| Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients | II | Telmisartan vs. placebo | University of Hawaii, USA | NCT04360551 |
| COVID MED Trial – Comparison of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED) | II/III | Losartan vs. lopinavir/ritonavir vs. hydroxychloroquine sulfate vs. placebos | Bassett Healthcare, USA | NCT04328012 |
| Coronavirus Response – Active Support for Hospitalised Covid-19 Patients (CRASH-19) | III | Standard of care vs. aspirin vs. losartan vs. simvastatin | London School of Hygiene and Tropical Medicine, UK | NCT04343001 |
| Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 (COVID-Aging) | III | Standard of care vs. hydroxychloroquine vs. azithromycin vs. telmisartan |
University Hospital, Strasbourg, France | NCT04359953 |
| Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients with Symptomatic SARS-CoV-2 Infection (COVID-19) (COVERAGE) | III | Dietary supplement: vitamins vs. imatinib vs. telmisartan |
University Hospital, Bordeaux, University of Bordeaux, France | NCT04356495 |
| Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection | IV | Losartan | Sharp HealthCare, La Mesa, California, USA | NCT04340557 |
| Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease | IV | Valsartan vs. placebo | Radboud University, The Netherlands | NCT04335786 |
| Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (CLARITY) | IV | Standard of care plus angiotensin receptor blockers vs. standard of care | The George Institute, Australia | NCT04394117 |